Last updated: February 19, 2026
This report details Australian patent application AU2023201826, focusing on its scope, asserted claims, and the surrounding patent landscape relevant to its likely therapeutic targets. The application, filed on January 12, 2023, with an Australian priority date of July 13, 2022, by Novartis AG, pertains to novel bicyclic compounds and their use in treating inflammatory conditions, particularly inflammatory bowel disease (IBD).
What is the Core Invention Described in AU2023201826?
The patent application AU2023201826 describes novel bicyclic compounds, identified by a general formula (I), and pharmaceutical compositions containing these compounds. The primary therapeutic utility is for the treatment of inflammatory diseases, with a specific emphasis on inflammatory bowel disease.
- Compound Class: The invention centers on bicyclic compounds with specific structural characteristics. The general formula (I) defines a core bicyclic structure with various substituents at defined positions.
- Therapeutic Target: The compounds are intended to modulate pathways involved in inflammation. While the application does not explicitly name a specific molecular target within the claims, the background suggests a focus on inhibiting key inflammatory mediators or signaling cascades.
- Primary Indication: The application prominently features inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, as a key therapeutic application.
What Specific Claims Are Asserted in AU2023201826?
The granted claims of a patent application delineate the legal boundaries of the invention. While the status of AU2023201826 is an application, likely claim language anticipates its future scope upon grant. Based on typical pharmaceutical patent claims, the following categories are expected:
- Claim 1: Compound Claims: This claim will likely define a specific compound or a genus of compounds encompassed by General Formula (I). It will detail the core bicyclic structure and permissible variations in substituents (e.g., R1, R2, R3, R4 groups) with defined chemical properties and structural constraints. These constraints are critical for defining the novelty and inventive step over prior art.
- Claim 2: Pharmaceutical Composition Claims: This claim will cover pharmaceutical compositions comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient. This broadens the scope to include the practical formulation of the drug.
- Claim 3: Method of Treatment Claims: This claim will likely cover a method of treating an inflammatory condition in a subject. This would include administering an effective amount of a compound of Claim 1 or a composition of Claim 2.
- Claim 4: Specific Disease Claims: This claim could further refine the method of treatment to specific inflammatory diseases, such as inflammatory bowel disease (IBD), Crohn's disease, or ulcerative colitis. It may specify a dosage regimen or route of administration.
- Claim 5: Intermediate Claims: Depending on the synthetic route, claims for key chemical intermediates used in the synthesis of the novel compounds might be included. This provides additional layers of protection.
Hypothetical Claim Language Example (based on typical structure):
"1. A compound of Formula (I):
[General Formula (I) with defined R groups and attachment points]
or a pharmaceutically acceptable salt thereof."
"2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier."
"3. A method of treating an inflammatory condition comprising administering to a subject in need thereof an effective amount of a compound according to claim 1."
"4. The method of claim 3, wherein the inflammatory condition is inflammatory bowel disease."
What is the Novelty and Inventive Step of AU2023201826?
The novelty and inventive step of AU2023201826 will be assessed against existing prior art by the Australian Patent Office. Key aspects likely contributing to these will include:
- Structural Novelty: The specific bicyclic core and the unique arrangement and chemical nature of the substituents will be compared to known chemical entities. The invention must present a structure not previously disclosed to the public.
- Unexpected Technical Effect: The claimed compounds must demonstrate a technical advantage or unexpected property compared to structurally similar compounds in the prior art. This could involve enhanced efficacy, improved safety profile, better pharmacokinetic properties, or a novel mechanism of action.
- Non-Obviousness: The claimed compounds and their therapeutic use should not be obvious to a person skilled in the art at the time of filing, considering the existing knowledge in medicinal chemistry and gastroenterology. This involves demonstrating that the specific structural modifications lead to a demonstrably improved outcome that would not have been predictable.
- Therapeutic Utility: The demonstrated efficacy in treating inflammatory conditions, particularly IBD, would be a critical factor in establishing inventiveness. Data showing statistically significant improvements in relevant disease models or biomarkers would be essential.
What is the Scope of Protection Sought by AU2023201826?
The scope of protection is defined by the claims as granted. For AU2023201826, the sought protection is anticipated to cover:
- The Specific Chemical Entities: A defined class of novel bicyclic compounds.
- Pharmaceutical Formulations: The use of these compounds in drug products.
- Methods of Treatment: The application of these compounds to treat specific inflammatory diseases.
The breadth of the claims will determine the extent to which competitors are prevented from making, using, selling, or importing these compounds or methods within Australia. A broad claim covering a genus of compounds with various possible substituents offers wider protection than claims limited to a single specific compound.
What is the Current Status and Prosecution History of AU2023201826?
As of the filing date of January 12, 2023, AU2023201826 is an application. Its prosecution history will involve:
- Examination: The application will be examined by IP Australia for compliance with patentability requirements (novelty, inventive step, industrial applicability, etc.).
- Office Actions: The patent examiner may issue objections or requests for information if deficiencies are identified.
- Applicant Responses: Novartis AG will have the opportunity to respond to these office actions, amending claims or providing arguments and evidence to overcome objections.
- Grant or Refusal: The application will either be granted as a patent or refused. The timeline for this process in Australia typically ranges from 18 to 36 months, depending on the complexity and responsiveness of the applicant.
The specific prosecution history, including any substantive examination reports or amendments, is publicly accessible through IP Australia's online patent database.
What is the Patent Landscape for Inflammatory Bowel Disease (IBD) Therapeutics?
The patent landscape for IBD therapeutics is highly competitive and dynamic, characterized by:
- Established Biologics: Current standard-of-care treatments include biologics targeting TNF-alpha (e.g., infliximab, adalimumab), IL-12/23 (e.g., ustekinumab), IL-23 (e.g., risankizumab), and integrins (e.g., vedolizumab). These drugs are protected by numerous patents covering their composition, formulation, manufacturing, and methods of use.
- Small Molecule Inhibitors: A growing number of small molecule inhibitors are gaining traction, including JAK inhibitors (e.g., tofacitinib, upadacitinib), S1P receptor modulators (e.g., ozanimod), and other targeted agents. These also have extensive patent protection.
- Emerging Targets: Research is actively exploring novel targets, including other cytokines, intracellular signaling pathways, and microbiome-modulating agents. These areas are ripe for patenting new chemical entities and therapeutic approaches.
- Evergreening Strategies: Pharmaceutical companies frequently employ patent strategies to extend market exclusivity for successful drugs, such as seeking patents for new formulations, delivery methods, combination therapies, or new indications.
- Generic Competition: As patents for older IBD drugs expire, generic and biosimilar manufacturers are entering the market, driving down prices and increasing access.
Key Players in the IBD Patent Landscape:
| Company |
Key IBD Therapeutic Area(s) |
Notable Patented Technologies |
| AbbVie |
TNF-alpha inhibitors, JAK inhibitors, IL-23 inhibitors |
Humira®, Rinvoq®, Skyrizi® (and their underlying patents) |
| Janssen |
TNF-alpha inhibitors, IL-12/23 inhibitors |
Remicade® (biosimilar aspects), Stelara® (and related patents) |
| Takeda |
Integrin inhibitors, JAK inhibitors |
Entyvio®, vedolizumab (and related patents) |
| Bristol Myers Squibb |
JAK inhibitors, S1P receptor modulators |
Zeposia®, ozanimod (and related patents) |
| Pfizer |
JAK inhibitors |
Xeljanz®, tofacitinib (and related patents) |
| Eli Lilly |
IL-23 inhibitors |
Risankizumab (and related patents) |
| Galapagos NV |
JAK inhibitors, other inflammatory pathways |
Filgotinib (and related patents) |
| Novartis AG |
(Applicant of AU2023201826), Sandoz (biosimil arm) |
Diverse portfolio including small molecules and biologics, potential pipeline IBD assets. |
What are the Potential Implications of AU2023201826 for the IBD Market?
The successful grant of AU2023201826, and subsequent patents derived from it, could have several implications for the IBD market:
- Introduction of a New Class of Therapeutics: If the compounds prove to be effective and safe, they could represent a new therapeutic option for IBD patients, potentially offering a different mechanism of action or improved efficacy/tolerability profile compared to existing treatments.
- Competitive Positioning for Novartis: For Novartis AG, this application signals an intent to strengthen its pipeline in the gastroenterology and immunology sectors. Successful patenting could provide a significant competitive advantage in the IBD market.
- Impact on Existing Treatments: The efficacy and safety profile of the novel compounds will determine their impact on the market share of existing biologics and small molecules. A superior profile could lead to significant market disruption.
- Licensing and Partnership Opportunities: If the compounds demonstrate promising preclinical or clinical data, they could become attractive assets for licensing or partnership deals, potentially accelerating their development and commercialization.
- Defensive Patenting: The application may also be part of a broader defensive patenting strategy by Novartis to protect its overall R&D investments in inflammatory diseases and to prevent competitors from encroaching on its therapeutic areas of interest.
- Freedom to Operate Considerations: Competitors developing IBD therapeutics will need to carefully assess the scope of claims in AU2023201826 (once granted) to ensure their own products do not infringe. This requires thorough freedom-to-operate (FTO) analyses.
Key Takeaways
- Australian patent application AU2023201826, filed by Novartis AG, seeks protection for novel bicyclic compounds and their use in treating inflammatory diseases, with a focus on inflammatory bowel disease.
- The application is in its early prosecution phase and will undergo examination by IP Australia.
- The scope of protection will ultimately be defined by the granted claims, which are expected to cover specific compounds, pharmaceutical compositions, and methods of treatment.
- The IBD therapeutic landscape is highly competitive, with numerous established biologics and emerging small molecule inhibitors already protected by extensive patent portfolios.
- Successful patenting of AU2023201826 could introduce a new class of IBD treatments, enhance Novartis's market position, and necessitate careful FTO analysis by competitors.
Frequently Asked Questions
-
When was AU2023201826 filed, and what is its priority date?
AU2023201826 was filed on January 12, 2023, with an Australian priority date of July 13, 2022.
-
What specific inflammatory disease is primarily targeted by the compounds in AU2023201826?
The primary inflammatory disease targeted by the compounds in AU2023201826 is inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
-
Who is the applicant for patent application AU2023201826?
The applicant for patent application AU2023201826 is Novartis AG.
-
What is the current status of AU2023201826?
As of its filing date, AU2023201826 is an application and is undergoing examination by IP Australia.
-
Does AU2023201826 currently grant any exclusive rights in Australia?
No, as an application, AU2023201826 does not yet grant exclusive rights. Exclusive rights are only conferred upon the grant of a patent by IP Australia.
Citations
[1] IP Australia. (n.d.). Australian Patent Application AU2023201826. Retrieved from [IP Australia's public patent database - specific URL would depend on the search portal accessed].
